Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6902845 | 1.00 | PTPN1 (0.61) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL11571568 | 0.92 | PTPN1 (0.48) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL11571569 | 0.92 | PTPN1 (0.48) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL6907667 | 0.82 | KDM1A (0.59) | PTPN1MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL6907669 | 0.82 | KDM1A (0.59) | PTPN1MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL10411567 | 0.81 | PTPN1 (0.61) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL13277590 | 0.81 | PTPN1 (0.61) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL10411568 | 0.81 | PTPN1 (0.61) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL214389 | 0.81 | PTPN1 (0.61) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL31211760 | 0.81 | PTPN1 (0.61) | PTPN1LMNAPTGS1PDE4ASNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703527-B2 | REACTING ALLYL ALCOHOL COMPOUND SUCH AS 2E,6E-3,7,11-TRIMETHYL-2,6,10-DODECATRIEN-1-OL WITH HYDRIDE ACCEPTOR SUCH AS 2-NITROBENZALDEHYDE IN THE PRESENCE OF AN ALUMINIUM ALKOXIDE AS AN OPPENAUER OXIDATION CATALYST | NIKKEN CHEMICALS CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20020198411-A1 | Method for oxidation of allyl alcohol | NIKKEN CHEMICALS CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198411-A1 | Method for oxidation of allyl alcohol | ADH1A, ADH1C, ADH5 | PTPN1 4791/4885LMNA 4281/4885PTGS1 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.